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Abstract
Background: Invasive pulmonary aspergillosis (IPA) is a rapid, progressive, fatal disease that
occurs mostly in immunocompromised patients. Patients with severe liver disease are at a
heightened risk for infections. Little is known about the clinical presentation including predisposing
factors and treatment of IPA in patients with hepatic failure.
Methods: Medical records of patients with hepatic failure between November 2005 and February
2007 were reviewed for lung infection. Nine medical records of definitive diagnosis of IPA and three
of probable IPA were identified.
Results: The main predisposing factors were found to be prolonged antibiotic therapy and steroid
exposure. Clinical signs and radiological findings were non-specific and atypical. Timely use of
caspofungin was found to reduce the mortality due to the disease.
Conclusion: A high index of suspicion is required for early IPA diagnosis in patients with hepatic
failure.
Background
Aspergillus is a saprophytic filamentous fungus widespread
in the environment, and has attracted attention in recent
years for its association with various clinical conditions,
depending essentially on the host's immunological status
[1,2]. In immunocompetent patients, pulmonary
aspergilloma, allergic aspergillus tracheobronchitis and
obstructive bronchial aspergillosis are described. In
immunocompromised patients, it can invade the pulmo-
nary parenchyma, resulting in invasive pulmonary
aspergillosis (IPA), a disease with high lethality [1-4].
Patients with severe liver disease are at a higher risk for
various infections [5,6]. Little is known about the clinical
presentation and treatment of IPA in patients with hepatic
failure. The available literature is confined to a few case
reports or series of reports only, with data mainly based
on autopsy reports. The aim of the present study was to
determine the clinical presentation and outcome of
aspergillosis in patients with hepatic failure. In contrast to
other reports, only one out of 12 patients diagnosed with
IPA died. We have analyzed predisposing factors and
treatment regimen, in an effort to determine the basis for
low mortality in our patient cohort.
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Methods
This was a retrospective study, conducted in Shanghai
Public Health Clinical Center, a tertiary care hospital spe-
cializing in infectious diseases, especially hepatic diseases.
Between November 2005 and February 2007, a total of
276 patients with hepatic failure were admitted. Medical
and microbiological records as well as the chest radio-
graphic imaging of all patients with hepatic failure and
accompanying lung infection were reviewed. Patients'
demography, duration of admission, predisposing factors,
clinical features, investigations, treatment and outcome
were noted.
Standardized criteria from European Organization for
Research and Treatment of Cancer and the Mycosis Study
Group of the National Institute of Allergy and Infectious
Disease (EORTC/MSG) [7] were applied for the diagnosis
of definite and probable IPA. Definite IPA was defined as
the demonstration of filamentous fungi by microscopy
from tissue samples with or without a positive culture for
Aspergillus. Probable IPA was defined as the demonstra-
tion of filamentous fungi compatible with the morphol-
ogy of Aspergillus and/or a positive culture for Aspergillus
from bronchoalveolar lavage (BAL) specimen in patients
in conjunction with 1 major (halo or "air crescent" on
computed tomography (CT) scan) or at least two minor
(signs of lower respiratory tract infection, pleural rub, and
presence of any new infiltrate in a patient who did not ful-
fill the major criterion but for whom no alternative diag-
nosis was available) clinical findings. IPA developing after
48 hours of hospital admission and before the clinical
diagnosis of fungal infection was considered nosocomial;
otherwise, the fungal infection was regarded as commu-
nity acquired.
Serological diagnosis, such as galactomannan or β-d-glu-
can, are not performed in Shanghai Public Health Clinical
Center; thoracic CT imaging combined with the patient's
condition despite antibiotic treatment was the main
approach for preliminary diagnosis of IPA. In brief,
appearance of pulmonary consolidation or infiltrate and
rapid progression on thoracic CT scan with antibiotic
resistant fever in the appropriate host setting was diag-
nosed as suspected IPA. Single-bed hospital room was
provided for the patient with high index of suspicion of
IPA. In patients with pulmonary infiltrates, especially
those with diffuse pulmonary infiltrates, fiberoptic bron-
choscopy with BAL and/or transbronchial lung biopsy
(TBLB) was performed. In patients with focal pulmonary
lesions, percutaneous puncture lung biopsy (PPLB) was
considered the first-line diagnostic tool. BAL or lung
biopsy was performed at the request of the treating physi-
cian with informed consent.
Thoracic CT scan was performed early in patients sus-
pected of having IPA, and twice a week for early detection
of IPA or preliminary evaluation of antifungal therapy.
Results of chest X-ray and thoracic CT scan were described
as normal, grand gross attenuation, non-specific infil-
trates and consolidation, pleural fluid, nodular lesion(s),
halo sign, air-crescent sign, and cavitation. The CT halo
sign is described as a surrounding halo of ground glass
attenuation surrounding a pulmonary nodule or mass
and corresponds to a central fungal nodule surrounded by
a rim of hemorrhage and coagulative necrosis. The air-
crescent sign is described as a pulmonary cavitation [8].
All continuous data were expressed either as mean and
standard deviation (SD), or median and range based on
the distribution.
The study was approved by the Research Ethics Commit-
tee, Shanghai Public Health Clinical Center, Fudan Uni-
versity.
Results
Examination of the medical records of all 276 patients
admitted to Shanghai Public Health Clinical Center with
hepatic failure identified 18 patients who had suspected
IPA with a negative sputum culture; of these, seven had
suspected IPA on admission. Chest CT showed that all
patients had a two fold increase in lesion volume within
the first three days despite broad spectrum antibiotic treat-
ment. Among the 18 patients, one stopped treatment due
to economic constraints; two objected to invasive exami-
nation but agreed to antifungal therapy. Six patients
underwent BAL; of these, two patients also had TBLB.
Lung biopsy was carried out in 12 patients, of which eight
were TBLB and four were PPLB. Five patients had a posi-
tive BAL culture for Aspergillus, but biopsy did not show
any abnormalities in the tracheobronchial tree. Nine of
twelve biopsies were histologically positive for Aspergillus,
the others were positive for Enterococcus faecium, Cytomeg-
alovirus  and  Mucor, respectively. Thus, a total of 12
patients were involved in this study, with definitive diag-
nosis of IPA in 9 and probable IPA in 3 patients. The
median time to diagnosis was 8 days (range 1–22 days)
after admission. Among the patients who underwent
biopsy, nine had no complications, one case had pneu-
mothorax with lung compressed to less than 20% and 2
cases presented with hemoptysis.
All 12 were referral cases; five of them were transferred for
deteriorated pneumonia from local hospitals and sus-
pected of IPA at admission. The initial status of all 12
patients at admission is listed in Table 1. The cause of
hepatic failure was hepatitis B virus (HBV) infection in
eleven patients, and coinfection with HBV and hepatitis
delta virus (HDV) in one patient. IPA was nosocomiallyBMC Gastroenterology 2008, 8:32 http://www.biomedcentral.com/1471-230X/8/32
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acquired in all patients, but none of these infections were
acquired in the intensive care unit.
The chief symptoms were mild to moderate fever and
decrease in mental function. Eight patients (66.7%) did
not have any respiratory symptoms (Table 2). All had
non-specific radiological findings. The halo and air-cres-
cent sign were evident in only two patients (Table 2). CT
brain scan was performed in six patients who had psychi-
atric symptoms; one patient was found to have a mass-like
low density lesion with a surrounding halo in the right
temporal lobe and clinically diagnosed as having
encephalic aspergillosis. Clinical features of IPA patients
before antifungal treatment are summarized in Table 3.
All patients received antibiotic therapy and nine patients
had steroid exposure before IPA diagnosis (Table 1). Ster-
oids were used as prevention for allergic reactions to
plasma, or to decrease persistent hyperbilirubinemia. The
maximum amount of steroids administrated was 1.8 gram
of methylprednisolone in one patient.
Patients were hospitalized for 15 to 221 days. Six patients
were in intensive care unit for ten or more days with
APECHE II score range from 17–29, four required nonin-
vasive assisted ventilation, and one died two days after
definite diagnosis.
The median time from suspicion of fungal infection to
antifungal treatment was 4 days (range from 1 ~ 16 days).
All patients (except the one patient who died) were
administrated caspofungin as antifungal agent after diag-
noses for at least 3 weeks (3–12 weeks), the patient with
endocranial aspergillosis received additional voricona-
zole for six months. Cessation of antifungal treatment is
subjectively judged by physicians based on patient's
improved condition, disappearance of clinical symptoms,
and improved laboratory tests. CT scan imaging was not
used as the evaluation measure, as four patients still had
small lamellar high density lesion on CT imaging. After a
median follow-up of 7 months (range from 4 to 11
months), all surviving patients were well, the residual
lesion on CT scan disappeared in three cases, with signifi-
cant decrease in a fourth patient.
Discussion
The development of IPA is almost always observed in
immunosuppressed individuals with an impairment or
deficiency of phagocyte function [9]. It has been previ-
ously demonstrated that decompensated liver disease is
an acquired immune deficiency state [5,6]; dysmetabo-
lism and malnutrition are also contributing factors.
Patients with severe liver disease are more prone to vari-
ous infections. Patients in our study presented two risk
factors for invasive pulmonary aspergillosis, broad spec-
trum antibiotic usage and steroid exposure, according to
the criteria defined by the EORTC/MSG [7]. These ele-
ments lend to the notion that narrow-spectrum antibiotic
is preferred and long term antibiotic treatment should be
avoided; corticosteroids should be used with caution in
patients with hepatic failure.
Most patients in this study had atypical clinical presenta-
tion often disregarded by physicians due to underlying
hepatic dysfunction and hepatic encephalopathy, and
radiological features were no different from bacterial
pneumonias. It should be noted that nine of twelve (75%)
Table 1: Demographic features of 12 patients with IPA
Characteristic Number of patients
Age in years (mean ± S.D.) 41.9 ± 9.5
Males (%) 87.5
Disease onset
Acute hepatic failure 0
Subacute hepatic failure 3
Chronic hepatic failure 9
Complications
Hepatic encephalopathy 5
Hepatorenal syndrome 3
Spontaneous bacterial peritonitis 3
MELD score (median, range) 30 (22–51)
Antibiotic usage
Duration (days, mean ± S.D.) 23.1 ± 8.6
One antibiotic 5
Two antibiotics 4
Three or more antibiotics 3
Steroid exposure 9
Table 2: Clinical and laboratory parameters of patients with IPA
Signs or symptoms Number of patients
Fever 12
Cough 3
Chest pain 0
Hemoptysis 0
Crackles 1
Chest X-ray findings
Changes in bilateral lung fields 9
Bilateral lung fields diffused 2
Right unilateral lung 2
Left upper lobe 4
Halo and air-crescent 2
Laboratory findings
Hemoglobin (g/L, mean ± S.D.) 95.7 ± 15.9
Leukocyte counts (×10 9/L, mean ± S.D.) 11.6 ± 7.9
Neutrophils (%, mean ± S.D.) 81.2 ± 6.4
Thrombocyte count (×109/L, mean ± S.D.) 102.7 ± 69.5
Total bilirubin (μmol/L, mean ± S.D.) 661.3 ± 189.7
Prothrombin activity (%, range) 8–26
HBV viral load (copies/ml, range) 104–107BMC Gastroenterology 2008, 8:32 http://www.biomedcentral.com/1471-230X/8/32
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biopsies performed on patients with suspected IPA con-
firmed this diagnosis. This rate was achieved because a
high index of suspicion exists for the occurrence of inva-
sive pulmonary aspergillosis in patients with hepatic fail-
ure. An aggravated condition during the usage of
antibiotics, such as an unexpected breakdown in mental
status, a marked increase in total serum bilirubin, a
decrease in PTA with antibiotic resistant fever, indicates
suspected fungal infection [10]. Although Candida monilia
is the most common pathogen in clinical fungal infection,
the change in leukocyte counts and percentage of neu-
trophils may be used for differential diagnosis of Candida
monilia and Eurotium infection [11]. A rapid progression
on thoracic CT scan with no response to antibiotic therapy
would reinforce the judgment [8]. In our study, the leuko-
cyte counts were elevated in 91.7 (11/12) patients, with
increased percentage of neutrophils in all patients.
In our study, caspofungin dramatically reversed the high
mortality of the disease reported by others [12,13], while
therapy to rebuild the immune system was not adopted,
as hepatic injury caused by HBV uses immunological
mechanisms.
Conclusion
Atypical clinical presentation of IPA was found in 12
patients with hepatic failure, suggesting that a high index
of suspicion is required for timely diagnosis of IPA. Early
and effective anti-fungal treatment greatly improves the
prognosis.
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